data_1nj0_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1nj0 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.818 0.342 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 3.9 m80 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.421 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' CE1' HG21 ' A' ' 18' ' ' THR . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.433 HG21 ' CE1' ' A' ' 16' ' ' TYR . 46.0 p . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.82 0.343 . . . . 0.0 110.653 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.424 HG21 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.434 ' CZ ' HG23 ' A' ' 18' ' ' THR . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 63.0 p . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.407 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 3.3 ptt85 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.86 0.362 . . . . 0.0 111.073 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.407 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 18.4 m170 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.412 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.412 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.442 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 21.5 p . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.801 0.334 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.2 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.067 0 CA-C-O 120.814 0.34 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.458 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.458 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.2 p . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.441 HG21 ' CE2' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.407 ' N ' ' CD1' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CE2' HG21 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 10.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.929 0.395 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.0 m-70 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.526 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.474 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CE1' HG23 ' A' ' 18' ' ' THR . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.4 HG23 ' CE1' ' A' ' 16' ' ' TYR . 36.3 p . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.855 0.36 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.458 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.458 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.451 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 47.9 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.94 0.4 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.53 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.53 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.486 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.486 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 22.0 p . . . . . 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 120.93 0.395 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.446 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.462 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 17.7 p . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.456 -0.173 0 CA-C-O 120.799 0.333 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.528 HG22 ' CG ' ' A' ' 16' ' ' TYR . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.411 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.411 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.421 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.528 ' CG ' HG22 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.3 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 26.1 ptt-85 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.467 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.434 ' CE1' HG23 ' A' ' 18' ' ' THR . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 HG23 ' CE1' ' A' ' 16' ' ' TYR . 19.5 p . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.124 0 CA-C-O 120.981 0.419 . . . . 0.0 110.888 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.426 HG22 ' CD1' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.402 ' CD1' ' N ' ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.426 ' CD1' HG22 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 120.783 0.325 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.505 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.43 ' CE1' HG21 ' A' ' 18' ' ' THR . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.43 HG21 ' CE1' ' A' ' 16' ' ' TYR . 6.6 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.0 mtt-85 . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.98 0.419 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.436 HG12 ' CE1' ' A' ' 16' ' ' TYR . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.451 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 19.8 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.895 0.379 . . . . 0.0 110.783 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.403 ' CG1' HG21 ' A' ' 18' ' ' THR . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.4 ' N ' ' CD1' ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.503 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.503 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 15.0 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.1 mtm-85 . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.794 0.33 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.418 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 6.3 m170 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.442 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.442 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.418 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.7 p . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.855 0.359 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.461 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.479 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.425 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 16.9 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.422 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.422 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.505 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.468 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.417 ' CG2' ' CG ' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.468 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.4 mtt180 . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.74 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.471 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.471 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 14.1 m80 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.446 ' CE1' HG21 ' A' ' 18' ' ' THR . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.446 HG21 ' CE1' ' A' ' 16' ' ' TYR . 18.4 p . . . . . 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.934 0.397 . . . . 0.0 110.644 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.463 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.406 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.474 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.474 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 10.7 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.414 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.434 ' CE1' HG21 ' A' ' 18' ' ' THR . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 HG21 ' CE1' ' A' ' 16' ' ' TYR . 27.9 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.445 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.424 ' CZ ' HG21 ' A' ' 18' ' ' THR . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.424 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.437 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.537 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.537 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD1' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 121.082 0.468 . . . . 0.0 110.766 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CE1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.476 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.457 ' CE1' HG12 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 HG23 ' CE1' ' A' ' 16' ' ' TYR . 1.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.972 0.415 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.446 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.416 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.416 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 82.7 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.944 0.402 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.441 ' CG2' ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . 0.402 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 6.8 m170 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.436 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.489 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.409 ' CG2' ' CD1' ' A' ' 7' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 121.001 0.429 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.436 HG22 ' CD1' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.444 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.444 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.436 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.6 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.429 ' HB2' ' CG2' ' A' ' 17' ' ' THR . 2.6 mtm-85 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.961 0.41 . . . . 0.0 111.399 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . 0.424 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.424 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.433 ' CZ ' HG23 ' A' ' 18' ' ' THR . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.433 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 46.3 p . . . . . 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.6 mmt-85 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.03 142.52 49.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.817 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -148.41 132.06 16.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.114 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.416 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 3.9 m80 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.421 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.421 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' CE1' HG21 ' A' ' 18' ' ' THR . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.433 HG21 ' CE1' ' A' ' 16' ' ' TYR . 46.0 p -107.67 -68.22 0.91 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.6 mmtm . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.293 -0.861 . . . . 0.0 111.005 -179.999 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.723 0.297 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.14 135.69 52.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.041 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.92 117.59 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.653 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.424 HG21 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.434 ' CZ ' HG23 ' A' ' 18' ' ' THR . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 63.0 p -110.65 -74.51 0.64 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.6 tmmm? . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.92 -179.941 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.0 mtt180 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.789 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.497 ' HG2' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -55.48 139.8 42.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.184 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.407 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 3.3 ptt85 -146.44 109.12 4.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.073 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.407 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 18.4 m170 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.412 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.412 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.497 ' HA ' ' HG2' ' A' ' 5' ' ' LYS . 21.5 p -103.49 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.9 tttt . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.288 -0.863 . . . . 0.0 110.865 179.975 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.885 0.374 . . . . 0.0 111.211 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.449 ' CE ' ' CE2' ' A' ' 16' ' ' TYR . 0.0 OUTLIER -63.26 159.74 17.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.757 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -140.82 91.18 2.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.285 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.402 ' CG1' ' HE3' ' A' ' 5' ' ' LYS . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.417 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.417 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.449 ' CE2' ' CE ' ' A' ' 5' ' ' LYS . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.449 ' CG2' ' HE2' ' A' ' 5' ' ' LYS . 17.2 p -107.67 -63.89 1.26 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' N ' ' OG1' ' A' ' 18' ' ' THR . 13.8 tptm . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.252 -0.88 . . . . 0.0 110.845 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.852 0.358 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -56.34 165.31 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.019 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.98 120.09 10.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.458 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.458 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.2 p -106.39 -64.25 1.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.0 mmtt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.137 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 120.813 0.34 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.47 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -174.71 -165.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.921 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 -139.69 96.64 3.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.441 HG21 ' CE2' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.407 ' N ' ' CD1' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CE2' HG21 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.47 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 10.2 p -89.84 165.8 13.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 32.3 mttt . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.938 179.967 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.2 mtm-85 . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 120.776 0.322 . . . . 0.0 111.158 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.423 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -140.94 -171.16 3.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.006 179.949 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 -134.48 98.62 4.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.584 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.0 m-70 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.526 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.474 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.4 ' CE1' HG23 ' A' ' 18' ' ' THR . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.423 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 36.3 p -89.9 -174.15 4.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 pttt . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.87 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 CA-C-O 120.731 0.301 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' CG ' ' N ' ' A' ' 6' ' ' ARG . 2.1 ttmt -113.61 167.54 10.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.525 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.467 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 20.6 mtt180 -168.07 114.87 0.7 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.734 179.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.458 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.458 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.451 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 47.9 p -89.92 -173.38 3.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.985 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.753 0.311 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.49 ' HE3' ' HB ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -172.79 -178.57 1.9 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.086 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 -145.6 119.82 9.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.475 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.53 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.53 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.486 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.49 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 22.0 p -126.35 64.34 1.25 Allowed 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.5 mmtt . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.014 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.2 ttp180 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.846 0.355 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.474 ' CG ' ' N ' ' A' ' 6' ' ' ARG . 18.1 ttmt -96.58 164.92 12.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.474 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -160.32 118.13 2.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.446 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.446 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.462 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 17.7 p -94.83 -59.88 1.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.0 pttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.381 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.8 ptt180 . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.932 0.396 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 18.6 tttt -99.0 153.67 18.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.74 128.61 8.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.528 HG22 ' CG ' ' A' ' 16' ' ' TYR . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.411 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.411 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.421 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.528 ' CG ' HG22 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.3 p -133.38 -170.0 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.4 tptp . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.816 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.887 0.375 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' CG ' ' N ' ' A' ' 6' ' ' ARG . 2.4 ttmt -105.4 163.08 12.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.509 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.448 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 26.1 ptt-85 -154.7 120.39 5.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.693 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.467 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.467 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.434 ' CE1' HG23 ' A' ' 18' ' ' THR . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 HG23 ' CE1' ' A' ' 16' ' ' TYR . 19.5 p -90.08 -169.66 2.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.8 tptm . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.918 179.922 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 21.4 mtm-85 . . . . . 0 N--CA 1.487 1.425 0 CA-C-O 120.808 0.337 . . . . 0.0 111.232 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.2 OUTLIER -81.33 176.69 9.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.875 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.79 123.31 2.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.888 179.633 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.426 HG22 ' CD1' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.402 ' CD1' ' N ' ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.426 ' CD1' HG22 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.548 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 30.6 p -93.69 21.67 6.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.404 ' NZ ' ' CD1' ' A' ' 7' ' ' ILE . 3.6 tttt -115.0 154.22 29.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.386 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 -156.82 122.46 4.76 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.905 179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.404 ' CD1' ' NZ ' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.505 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.43 ' CE1' HG21 ' A' ' 18' ' ' THR . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.43 HG21 ' CE1' ' A' ' 16' ' ' TYR . 6.6 p -100.47 -171.82 2.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.882 179.884 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.871 0.367 . . . . 0.0 111.248 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.495 ' HD3' ' HA ' ' A' ' 18' ' ' THR . 1.1 ptpt -83.8 -171.25 3.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.176 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.404 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 42.0 mtt-85 -151.1 103.01 3.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.33 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.436 HG12 ' CE1' ' A' ' 16' ' ' TYR . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.495 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 19.8 p -117.26 -40.27 3.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 mtmt . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.861 179.957 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.837 0.351 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.542 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -159.37 172.67 17.53 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.432 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -162.63 119.53 1.97 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.783 179.293 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.403 ' CG1' HG21 ' A' ' 18' ' ' THR . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.4 ' N ' ' CD1' ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.503 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.542 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 15.0 p -96.04 137.38 35.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.231 -0.89 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.3 mmm180 . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.848 0.356 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.437 ' HG3' ' N ' ' A' ' 6' ' ' ARG . 0.2 OUTLIER -88.04 146.27 25.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.554 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.437 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.1 mtm-85 -123.23 84.95 2.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.051 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.418 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 6.3 m170 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.442 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.442 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.418 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.426 ' CE1' ' CE ' ' A' ' 5' ' ' LYS . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.421 ' CG2' ' HD2' ' A' ' 5' ' ' LYS . 4.7 p -89.98 -166.25 1.54 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.302 -0.856 . . . . 0.0 110.848 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.861 0.362 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.504 ' HE3' ' HB ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -120.79 -170.27 1.97 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.915 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 -147.97 107.51 3.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.786 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.461 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.479 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.479 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.504 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 p -117.99 -165.18 1.07 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.981 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.916 0.389 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.517 ' HG2' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -51.49 156.73 1.2 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.12 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.422 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 0.0 OUTLIER -136.75 115.37 12.0 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' HE2' ' A' ' 5' ' ' LYS . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.422 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.505 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.505 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.468 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.417 ' CG2' ' CG ' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.517 ' HA ' ' HG2' ' A' ' 5' ' ' LYS . 1.4 p -115.12 132.59 56.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.965 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.814 0.34 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.4 OUTLIER -82.05 -164.61 0.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.002 179.919 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.412 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.4 mtt180 -140.57 99.06 3.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.74 179.422 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.471 ' O ' ' CD2' ' A' ' 8' ' ' HIS . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.471 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 14.1 m80 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.446 ' CE1' HG21 ' A' ' 18' ' ' THR . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.462 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 18.4 p -112.01 32.47 5.47 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.4 pttp . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.907 179.988 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.2 mtm180 . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.966 0.412 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.519 ' HE2' ' OG1' ' A' ' 18' ' ' THR . 0.5 OUTLIER -177.89 155.29 0.98 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.946 -179.932 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.34 141.44 19.39 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.644 179.621 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.463 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.406 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.406 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.474 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.519 ' OG1' ' HE2' ' A' ' 5' ' ' LYS . 10.7 t -101.5 48.99 0.88 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.5 tptt . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.167 -0.921 . . . . 0.0 110.817 -179.995 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.004 0.431 . . . . 0.0 111.058 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.468 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.0 OUTLIER -53.4 -171.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.586 -179.739 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.414 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 51.1 ttt-85 -107.21 118.73 37.49 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 -179.046 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.467 HG13 ' CD ' ' A' ' 5' ' ' LYS . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.414 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.435 ' CE2' ' NZ ' ' A' ' 5' ' ' LYS . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.444 ' HA ' ' CB ' ' A' ' 5' ' ' LYS . 27.9 p -96.66 44.66 1.06 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.171 -0.919 . . . . 0.0 111.48 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 18.7 mtm180 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.857 0.36 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.521 ' HD2' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -46.73 142.91 3.03 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.475 179.798 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 -92.08 87.47 6.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.521 HG13 ' HD2' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.445 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.445 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.488 ' CE2' ' HE2' ' A' ' 5' ' ' LYS . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.465 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 1.4 p -96.21 -91.18 0.23 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.0 ttpt . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.896 -179.914 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 CA-C-O 120.856 0.36 . . . . 0.0 111.096 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.521 ' HG3' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -61.98 -155.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.672 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -93.15 50.54 1.54 Allowed 'General case' 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 179.667 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.437 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.537 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.537 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD1' HG12 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.521 ' HA ' ' HG3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -130.5 -174.36 3.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.268 -0.872 . . . . 0.0 110.89 179.956 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 120.962 0.41 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' CG ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -53.13 -175.03 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.813 -179.82 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -107.27 60.58 0.62 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.766 179.992 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CE1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.476 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.457 ' CE1' HG12 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.448 ' HA ' ' CG ' ' A' ' 5' ' ' LYS . 1.4 t -139.8 103.03 4.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.798 -179.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.813 0.34 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' HE2' ' HA ' ' A' ' 18' ' ' THR . 0.2 OUTLIER -135.21 -175.59 3.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.965 -179.887 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 -161.97 125.11 3.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.101 179.572 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.446 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.416 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' HA ' ' HE2' ' A' ' 5' ' ' LYS . 82.7 p -95.32 37.59 1.17 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.976 -179.968 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.775 0.321 . . . . 0.0 111.294 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.451 ' HE2' ' CA ' ' A' ' 18' ' ' THR . 0.2 OUTLIER -84.58 -172.52 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.981 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.93 123.31 4.02 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.894 179.551 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.441 ' CG2' ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.402 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 6.8 m170 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.436 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.489 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' CG2' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.451 ' CA ' ' HE2' ' A' ' 5' ' ' LYS . 0.5 OUTLIER -101.65 82.61 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.6 mmtt . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.926 -179.988 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.601 0.239 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.444 ' CG ' ' N ' ' A' ' 6' ' ' ARG . 0.9 OUTLIER -126.82 165.68 18.87 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 120.771 0.319 . . . . 0.0 110.346 -179.878 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -161.92 123.21 2.72 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.744 179.256 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.436 HG22 ' CD1' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.444 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.444 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.436 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.6 p -89.95 -53.85 4.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.866 -179.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 120.944 0.402 . . . . 0.0 111.261 . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.434 ' CE ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -49.92 172.69 0.02 OUTLIER 'General case' 0 CA--C 1.518 -0.273 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.378 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.429 ' HB2' ' CG2' ' A' ' 17' ' ' THR . 2.6 mtm-85 -126.65 109.33 11.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.399 -179.813 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.424 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.424 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.433 ' CZ ' HG23 ' A' ' 18' ' ' THR . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' HA ' ' CE ' ' A' ' 5' ' ' LYS . 46.3 p -133.25 -74.88 0.49 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.335 -0.841 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.818 0.342 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 16' ' ' TYR . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 8.7 m-70 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.449 ' HD2' HG23 ' A' ' 7' ' ' ILE . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 17' ' ' THR . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 46.0 p . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.82 0.343 . . . . 0.0 110.653 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.924 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.924 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 63.0 p . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.86 0.362 . . . . 0.0 111.073 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 15' ' ' PHE . 24.6 m-70 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.402 ' CB ' ' HB2' ' A' ' 8' ' ' HIS . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.442 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 21.5 p . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.801 0.334 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.691 HG22 HD11 ' A' ' 9' ' ' ILE . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD11 HG22 ' A' ' 7' ' ' ILE . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.429 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.2 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.067 0 CA-C-O 120.814 0.34 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.405 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 15' ' ' PHE . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.758 HD11 ' HB2' ' A' ' 16' ' ' TYR . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.401 ' HB2' ' HB2' ' A' ' 8' ' ' HIS . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.758 ' HB2' HD11 ' A' ' 9' ' ' ILE . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.2 p . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' CG ' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.626 ' N ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.412 ' H ' ' HG2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.689 ' CG ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.506 HG22 ' HE1' ' A' ' 16' ' ' TYR . 10.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.929 0.395 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.505 HG22 ' CD1' ' A' ' 9' ' ' ILE . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.51 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.51 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' ILE . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 36.3 p . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.855 0.36 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.432 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.616 ' CE1' HG23 ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.616 HG23 ' CE1' ' A' ' 16' ' ' TYR . 47.9 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.94 0.4 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.513 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.513 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.617 ' CD1' HG23 ' A' ' 7' ' ' ILE . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.486 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 22.0 p . . . . . 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 120.93 0.395 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.462 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 17.7 p . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.456 -0.173 0 CA-C-O 120.799 0.333 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.581 ' N ' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.434 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' C ' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.416 ' HD3' ' C ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.434 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.503 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 16' ' ' TYR . 6.3 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 26.1 ptt-85 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.5 p . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.124 0 CA-C-O 120.981 0.419 . . . . 0.0 110.888 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.567 HG23 ' HA ' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' ' HD2' ' A' ' 13' ' ' ARG . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.403 ' HD2' ' O ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.567 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 120.783 0.325 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.1 t-80 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 9' ' ' ILE . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.482 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.6 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.0 mtt-85 . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.98 0.419 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.699 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.409 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.699 ' CD1' HG23 ' A' ' 7' ' ' ILE . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.626 HG22 ' CE1' ' A' ' 16' ' ' TYR . 19.8 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.895 0.379 . . . . 0.0 110.783 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 9' ' ' ILE . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.597 ' C ' HD12 ' A' ' 9' ' ' ILE . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.638 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.543 ' CZ ' HG21 ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.543 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 15.0 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.1 mtm-85 . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.794 0.33 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.655 HG23 ' HD1' ' A' ' 16' ' ' TYR . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 8.5 m-70 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.419 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.655 ' HD1' HG23 ' A' ' 7' ' ' ILE . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.7 p . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.855 0.359 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.629 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.465 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.425 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 16.9 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.87 ' HG2' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.54 HG23 ' HD1' ' A' ' 16' ' ' TYR . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.582 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.488 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.488 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.54 ' HD1' HG23 ' A' ' 7' ' ' ILE . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.87 HG23 ' HG2' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.503 HG21 ' OH ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.4 mtt180 . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.74 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.58 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.465 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 30.9 m-70 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.58 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.531 HG22 ' HE1' ' A' ' 16' ' ' TYR . 18.4 p . . . . . 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.934 0.397 . . . . 0.0 110.644 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.465 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 7' ' ' ILE . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.402 ' CD ' ' N ' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.853 ' CZ ' HG22 ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.853 HG22 ' CZ ' ' A' ' 16' ' ' TYR . 10.7 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.557 HG23 ' CD2' ' A' ' 16' ' ' TYR . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.525 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.413 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.749 ' CE1' HG23 ' A' ' 18' ' ' THR . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' THR . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.749 HG23 ' CE1' ' A' ' 16' ' ' TYR . 27.9 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.649 HG23 ' HD2' ' A' ' 16' ' ' TYR . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.419 ' O ' ' N ' ' A' ' 15' ' ' PHE . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.649 ' HD2' HG23 ' A' ' 7' ' ' ILE . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.551 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.623 ' O ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 8' ' ' HIS . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.526 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB1' HD12 ' A' ' 9' ' ' ILE . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.605 ' HE1' HG23 ' A' ' 18' ' ' THR . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.605 HG23 ' HE1' ' A' ' 16' ' ' TYR . 0.6 OUTLIER . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.421 ' HB3' ' OG1' ' A' ' 17' ' ' THR . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 121.082 0.468 . . . . 0.0 110.766 . . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.527 ' O ' HD13 ' A' ' 9' ' ' ILE . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.527 HD13 ' O ' ' A' ' 8' ' ' HIS . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.455 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.71 ' CD1' HG23 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.421 ' OG1' ' HB3' ' A' ' 6' ' ' ARG . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.617 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.972 0.415 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.847 HD11 HG22 ' A' ' 18' ' ' THR . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.449 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.508 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.508 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.523 ' CE1' HG23 ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.847 HG22 HD11 ' A' ' 7' ' ' ILE . 82.7 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.944 0.402 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.93 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . 1.5 m-70 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.807 HD11 ' HB3' ' A' ' 16' ' ' TYR . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.441 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.93 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.449 ' O ' HG23 ' A' ' 17' ' ' THR . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.702 ' CG2' HD11 ' A' ' 7' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 121.001 0.429 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.638 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 8' ' ' HIS . . . . . 0.717 ' O ' HD13 ' A' ' 9' ' ' ILE . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.717 HD13 ' O ' ' A' ' 8' ' ' HIS . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.638 ' CD1' HG23 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.6 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.682 ' HB2' HG22 ' A' ' 17' ' ' THR . 2.6 mtm-85 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.961 0.41 . . . . 0.0 111.399 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 16' ' ' TYR . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.432 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.454 ' HD2' HG23 ' A' ' 7' ' ' ILE . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.682 HG22 ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.411 HG21 ' OH ' ' A' ' 16' ' ' TYR . 46.3 p . . . . . 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.6 mmt-85 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.1 OUTLIER -72.03 142.52 49.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.817 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -148.41 132.06 16.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.114 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.725 HD11 ' HD2' ' A' ' 5' ' ' LYS . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 8.7 m-70 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.449 ' HD2' HG23 ' A' ' 7' ' ' ILE . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 17' ' ' THR . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.852 HG22 ' HE3' ' A' ' 5' ' ' LYS . 46.0 p -107.67 -68.22 0.91 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.6 mmtm . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.293 -0.861 . . . . 0.0 111.005 -179.999 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.723 0.297 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.824 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -68.14 135.69 52.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.041 -179.915 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.92 117.59 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.653 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.924 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.924 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.824 HG22 ' HE3' ' A' ' 5' ' ' LYS . 63.0 p -110.65 -74.51 0.64 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.6 tmmm? . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.92 -179.941 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.0 mtt180 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.789 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.859 ' HE2' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -55.48 139.8 42.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.184 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -146.44 109.12 4.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.073 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.414 HG13 ' NZ ' ' A' ' 5' ' ' LYS . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 15' ' ' PHE . 24.6 m-70 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.402 ' CB ' ' HB2' ' A' ' 8' ' ' HIS . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.859 HG22 ' HE2' ' A' ' 5' ' ' LYS . 21.5 p -103.49 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.9 tttt . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.288 -0.863 . . . . 0.0 110.865 179.975 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.885 0.374 . . . . 0.0 111.211 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.737 ' CE ' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -63.26 159.74 17.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.757 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -140.82 91.18 2.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.285 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.691 HG22 HD11 ' A' ' 9' ' ' ILE . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD11 HG22 ' A' ' 7' ' ' ILE . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.429 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.737 HG22 ' CE ' ' A' ' 5' ' ' LYS . 17.2 p -107.67 -63.89 1.26 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' N ' ' OG1' ' A' ' 18' ' ' THR . 13.8 tptm . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.252 -0.88 . . . . 0.0 110.845 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.852 0.358 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.9 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -56.34 165.31 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.019 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.98 120.09 10.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.562 HD11 ' HE2' ' A' ' 5' ' ' LYS . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 15' ' ' PHE . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.758 HD11 ' HB2' ' A' ' 16' ' ' TYR . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.401 ' HB2' ' HB2' ' A' ' 8' ' ' HIS . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.758 ' HB2' HD11 ' A' ' 9' ' ' ILE . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.9 HG22 ' HE3' ' A' ' 5' ' ' LYS . 30.2 p -106.39 -64.25 1.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.0 mmtt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.137 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 120.813 0.34 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.726 ' CG ' HD11 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -174.71 -165.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.921 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 -139.69 96.64 3.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.726 HD11 ' CG ' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.626 ' N ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.412 ' H ' ' HG2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.689 ' CG ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.707 HG22 ' CE ' ' A' ' 5' ' ' LYS . 10.2 p -89.84 165.8 13.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 32.3 mttt . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.938 179.967 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.2 mtm-85 . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 120.776 0.322 . . . . 0.0 111.158 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.538 ' CE ' HG22 ' A' ' 18' ' ' THR . 0.1 OUTLIER -140.94 -171.16 3.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.006 179.949 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 -134.48 98.62 4.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.584 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.505 HG22 ' CD1' ' A' ' 9' ' ' ILE . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.0 m80 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.51 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.51 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' ILE . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.538 HG22 ' CE ' ' A' ' 5' ' ' LYS . 36.3 p -89.9 -174.15 4.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 pttt . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.87 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 CA-C-O 120.731 0.301 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.642 ' HD3' HD11 ' A' ' 7' ' ' ILE . 2.1 ttmt -113.61 167.54 10.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.525 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.467 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 20.6 mtt180 -168.07 114.87 0.7 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.734 179.355 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.642 HD11 ' HD3' ' A' ' 5' ' ' LYS . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.432 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.616 ' CE1' HG23 ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.616 HG23 ' CE1' ' A' ' 16' ' ' TYR . 47.9 p -89.92 -173.38 3.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.985 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.753 0.311 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.576 ' HE3' ' HB ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -172.79 -178.57 1.9 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.086 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 -145.6 119.82 9.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.475 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.8 t-80 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.513 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.513 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.617 ' CD1' HG23 ' A' ' 7' ' ' ILE . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.576 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 22.0 p -126.35 64.34 1.25 Allowed 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.5 mmtt . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.014 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.2 ttp180 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.846 0.355 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.576 ' HD3' HD11 ' A' ' 7' ' ' ILE . 18.1 ttmt -96.58 164.92 12.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.474 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -160.32 118.13 2.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.576 HD11 ' HD3' ' A' ' 5' ' ' LYS . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.492 HG22 ' HE2' ' A' ' 5' ' ' LYS . 17.7 p -94.83 -59.88 1.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.0 pttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.381 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.8 ptt180 . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.932 0.396 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.874 ' HE3' HG22 ' A' ' 18' ' ' THR . 18.6 tttt -99.0 153.67 18.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.74 128.61 8.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.581 ' N ' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.434 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' C ' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.416 ' HD3' ' C ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.434 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.503 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.874 HG22 ' HE3' ' A' ' 5' ' ' LYS . 6.3 p -133.38 -170.0 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.4 tptp . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.816 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.887 0.375 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.703 ' HE2' HG22 ' A' ' 18' ' ' THR . 2.4 ttmt -105.4 163.08 12.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.509 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.448 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 26.1 ptt-85 -154.7 120.39 5.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.693 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.703 HG22 ' HE2' ' A' ' 5' ' ' LYS . 19.5 p -90.08 -169.66 2.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.8 tptm . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.918 179.922 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 21.4 mtm-85 . . . . . 0 N--CA 1.487 1.425 0 CA-C-O 120.808 0.337 . . . . 0.0 111.232 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.747 ' HD3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -81.33 176.69 9.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.875 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.79 123.31 2.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.888 179.633 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.567 HG23 ' HA ' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' ' HD2' ' A' ' 13' ' ' ARG . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.403 ' HD2' ' O ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.567 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.747 HG22 ' HD3' ' A' ' 5' ' ' LYS . 30.6 p -93.69 21.67 6.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.587 ' CE ' HD11 ' A' ' 7' ' ' ILE . 3.6 tttt -115.0 154.22 29.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.386 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 -156.82 122.46 4.76 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.905 179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.587 HD11 ' CE ' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.1 t-80 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 9' ' ' ILE . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.482 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.509 HG22 ' CE ' ' A' ' 5' ' ' LYS . 6.6 p -100.47 -171.82 2.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.882 179.884 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.871 0.367 . . . . 0.0 111.248 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.796 ' HD2' HD11 ' A' ' 7' ' ' ILE . 1.1 ptpt -83.8 -171.25 3.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.176 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.411 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 42.0 mtt-85 -151.1 103.01 3.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.33 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.796 HD11 ' HD2' ' A' ' 5' ' ' LYS . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 2.9 t-80 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.409 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.699 ' CD1' HG23 ' A' ' 7' ' ' ILE . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.626 HG22 ' CE1' ' A' ' 16' ' ' TYR . 19.8 p -117.26 -40.27 3.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 mtmt . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.861 179.957 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.837 0.351 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.565 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -159.37 172.67 17.53 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.44 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -162.63 119.53 1.97 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.783 179.293 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 9' ' ' ILE . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.597 ' C ' HD12 ' A' ' 9' ' ' ILE . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.638 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.543 ' CZ ' HG21 ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.565 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 15.0 p -96.04 137.38 35.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.231 -0.89 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.3 mmm180 . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.848 0.356 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.72 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -88.04 146.27 25.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.554 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.441 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.1 mtm-85 -123.23 84.95 2.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.051 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.655 HG23 ' HD1' ' A' ' 16' ' ' TYR . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 8.5 m-70 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.419 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.655 ' HD1' HG23 ' A' ' 7' ' ' ILE . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.72 HG22 ' HE3' ' A' ' 5' ' ' LYS . 4.7 p -89.98 -166.25 1.54 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.302 -0.856 . . . . 0.0 110.848 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.861 0.362 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.588 ' HE2' HD11 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -120.79 -170.27 1.97 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.915 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 -147.97 107.51 3.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.786 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.588 HD11 ' HE2' ' A' ' 5' ' ' LYS . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.629 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.465 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.588 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 p -117.99 -165.18 1.07 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.981 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.916 0.389 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.772 ' HE2' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -51.49 156.73 1.2 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.12 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.87 ' HG2' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -136.75 115.37 12.0 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.772 HD11 ' HE2' ' A' ' 5' ' ' LYS . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.582 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.488 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.488 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.54 ' HD1' HG23 ' A' ' 7' ' ' ILE . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.87 HG23 ' HG2' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.598 HG22 ' HD3' ' A' ' 5' ' ' LYS . 1.4 p -115.12 132.59 56.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.965 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.814 0.34 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.656 ' HD2' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -82.05 -164.61 0.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.002 179.919 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.424 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.4 mtt180 -140.57 99.06 3.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.74 179.422 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.656 HD11 ' HD2' ' A' ' 5' ' ' LYS . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.465 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 30.9 m-70 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.58 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.628 HG22 ' HD3' ' A' ' 5' ' ' LYS . 18.4 p -112.01 32.47 5.47 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.4 pttp . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.907 179.988 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.2 mtm180 . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.966 0.412 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HE2' ' OG1' ' A' ' 18' ' ' THR . 0.5 OUTLIER -177.89 155.29 0.98 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.946 -179.932 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.34 141.44 19.39 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.644 179.621 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.465 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.3 m-70 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 7' ' ' ILE . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.402 ' CD ' ' N ' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.853 ' CZ ' HG22 ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.853 HG22 ' CZ ' ' A' ' 16' ' ' TYR . 10.7 t -101.5 48.99 0.88 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.5 tptt . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.167 -0.921 . . . . 0.0 110.817 -179.995 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.004 0.431 . . . . 0.0 111.058 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.0 OUTLIER -53.4 -171.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.586 -179.739 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.416 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 51.1 ttt-85 -107.21 118.73 37.49 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 -179.046 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.557 HG23 ' CD2' ' A' ' 16' ' ' TYR . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.525 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.413 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.749 ' CE1' HG23 ' A' ' 18' ' ' THR . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.485 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.749 HG23 ' CE1' ' A' ' 16' ' ' TYR . 27.9 p -96.66 44.66 1.06 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.171 -0.919 . . . . 0.0 111.48 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 18.7 mtm180 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.857 0.36 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.535 ' HD2' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -46.73 142.91 3.03 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.475 179.798 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 -92.08 87.47 6.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.649 HG23 ' HD2' ' A' ' 16' ' ' TYR . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.419 ' O ' ' N ' ' A' ' 15' ' ' PHE . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.649 ' HD2' HG23 ' A' ' 7' ' ' ILE . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.551 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p -96.21 -91.18 0.23 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.0 ttpt . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.896 -179.914 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 CA-C-O 120.856 0.36 . . . . 0.0 111.096 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.682 ' HG3' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -61.98 -155.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.672 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -93.15 50.54 1.54 Allowed 'General case' 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 179.667 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.623 ' O ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 8' ' ' HIS . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.526 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB1' HD12 ' A' ' 9' ' ' ILE . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.605 ' HE1' HG23 ' A' ' 18' ' ' THR . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.682 HG22 ' HG3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -130.5 -174.36 3.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.268 -0.872 . . . . 0.0 110.89 179.956 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 120.962 0.41 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.455 ' CG ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -53.13 -175.03 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.813 -179.82 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.421 ' HB3' ' OG1' ' A' ' 17' ' ' THR . 0.1 OUTLIER -107.27 60.58 0.62 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.766 179.992 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.527 ' O ' HD13 ' A' ' 9' ' ' ILE . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.527 HD13 ' O ' ' A' ' 8' ' ' HIS . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.455 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.71 ' CD1' HG23 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.421 ' OG1' ' HB3' ' A' ' 6' ' ' ARG . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.617 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 t -139.8 103.03 4.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.798 -179.972 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.813 0.34 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HE2' ' HA ' ' A' ' 18' ' ' THR . 0.2 OUTLIER -135.21 -175.59 3.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.965 -179.887 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 -161.97 125.11 3.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.101 179.572 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.847 HD11 HG22 ' A' ' 18' ' ' THR . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.449 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.508 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.508 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.523 ' CE1' HG23 ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.847 HG22 HD11 ' A' ' 7' ' ' ILE . 82.7 p -95.32 37.59 1.17 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.976 -179.968 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.775 0.321 . . . . 0.0 111.294 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.625 ' CD ' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -84.58 -172.52 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.981 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.93 123.31 4.02 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.894 179.551 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.93 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . 1.5 m-70 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.807 HD11 ' HB3' ' A' ' 16' ' ' TYR . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.441 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.93 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.449 ' O ' HG23 ' A' ' 17' ' ' THR . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.702 ' CG2' HD11 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -101.65 82.61 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.6 mmtt . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.926 -179.988 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.601 0.239 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.938 ' HD3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -126.82 165.68 18.87 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 120.771 0.319 . . . . 0.0 110.346 -179.878 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -161.92 123.21 2.72 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.744 179.256 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.938 HD11 ' HD3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.717 ' O ' HD13 ' A' ' 9' ' ' ILE . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.717 HD13 ' O ' ' A' ' 8' ' ' HIS . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.638 ' CD1' HG23 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.491 HG22 ' HE2' ' A' ' 5' ' ' LYS . 26.6 p -89.95 -53.85 4.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.866 -179.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 120.944 0.402 . . . . 0.0 111.261 . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.447 ' CE ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -49.92 172.69 0.02 OUTLIER 'General case' 0 CA--C 1.518 -0.273 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.378 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.682 ' HB2' HG22 ' A' ' 17' ' ' THR . 2.6 mtm-85 -126.65 109.33 11.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.399 -179.813 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 16' ' ' TYR . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.432 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.454 ' HD2' HG23 ' A' ' 7' ' ' ILE . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.682 HG22 ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.447 ' HA ' ' CE ' ' A' ' 5' ' ' LYS . 46.3 p -133.25 -74.88 0.49 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.335 -0.841 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.818 0.342 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.449 HG23 ' HD2' ' A' ' 16' ' ' TYR . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 3.9 m80 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.449 ' HD2' HG23 ' A' ' 7' ' ' ILE . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 17' ' ' THR . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 46.0 p . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.82 0.343 . . . . 0.0 110.653 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.924 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.924 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 63.0 p . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.425 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 3.3 ptt85 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.86 0.362 . . . . 0.0 111.073 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 18.4 m170 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.402 ' CB ' ' HB2' ' A' ' 8' ' ' HIS . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.442 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 21.5 p . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.801 0.334 . . . . 0.0 111.285 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.691 HG22 HD11 ' A' ' 9' ' ' ILE . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.691 HD11 HG22 ' A' ' 7' ' ' ILE . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.429 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.2 p . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.067 0 CA-C-O 120.814 0.34 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.405 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 15' ' ' PHE . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.758 HD11 ' HB2' ' A' ' 16' ' ' TYR . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.401 ' HB2' ' HB2' ' A' ' 8' ' ' HIS . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.758 ' HB2' HD11 ' A' ' 9' ' ' ILE . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.2 p . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' CG ' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.626 ' N ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.412 ' H ' ' HG2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.689 ' CG ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.506 HG22 ' HE1' ' A' ' 16' ' ' TYR . 10.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.929 0.395 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.505 HG22 ' CD1' ' A' ' 9' ' ' ILE . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.0 m-70 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.51 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.51 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' ILE . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 36.3 p . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.855 0.36 . . . . 0.0 110.734 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.432 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.616 ' CE1' HG23 ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.616 HG23 ' CE1' ' A' ' 16' ' ' TYR . 47.9 p . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.94 0.4 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.513 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.513 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.617 ' CD1' HG23 ' A' ' 7' ' ' ILE . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.486 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 22.0 p . . . . . 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 120.93 0.395 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.462 ' CG2' ' CZ ' ' A' ' 16' ' ' TYR . 17.7 p . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.456 -0.173 0 CA-C-O 120.799 0.333 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.581 ' N ' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.434 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.416 ' C ' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.416 ' HD3' ' C ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.434 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.503 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 16' ' ' TYR . 6.3 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 26.1 ptt-85 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 19.5 p . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.124 0 CA-C-O 120.981 0.419 . . . . 0.0 110.888 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.567 HG23 ' HA ' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' ' HD2' ' A' ' 13' ' ' ARG . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.403 ' HD2' ' O ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.567 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 30.6 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 120.783 0.325 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 9' ' ' ILE . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.482 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 6.6 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 42.0 mtt-85 . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.98 0.419 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.699 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.409 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.699 ' CD1' HG23 ' A' ' 7' ' ' ILE . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.626 HG22 ' CE1' ' A' ' 16' ' ' TYR . 19.8 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.895 0.379 . . . . 0.0 110.783 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 9' ' ' ILE . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.597 ' C ' HD12 ' A' ' 9' ' ' ILE . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.638 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.543 ' CZ ' HG21 ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.543 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 15.0 p . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.1 mtm-85 . . . . . 0 N--CA 1.455 -0.179 0 CA-C-O 120.794 0.33 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.655 HG23 ' HD1' ' A' ' 16' ' ' TYR . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 6.3 m170 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.419 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.436 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.655 ' HD1' HG23 ' A' ' 7' ' ' ILE . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.7 p . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.855 0.359 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.629 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.465 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.425 ' CG2' ' CE1' ' A' ' 16' ' ' TYR . 16.9 p . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.87 ' HG2' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.54 HG23 ' HD1' ' A' ' 16' ' ' TYR . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.438 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.488 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.488 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.54 ' HD1' HG23 ' A' ' 7' ' ' ILE . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.87 HG23 ' HG2' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.503 HG21 ' OH ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 14.4 mtt180 . . . . . 0 N--CA 1.452 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.74 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.58 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.471 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 14.1 m80 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.58 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.531 HG22 ' HE1' ' A' ' 16' ' ' TYR . 18.4 p . . . . . 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 120.934 0.397 . . . . 0.0 110.644 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.465 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 7' ' ' ILE . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.402 ' CD ' ' N ' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.853 ' CZ ' HG22 ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.853 HG22 ' CZ ' ' A' ' 16' ' ' TYR . 10.7 t . . . . . 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.557 HG23 ' CD2' ' A' ' 16' ' ' TYR . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.525 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.413 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.749 ' CE1' HG23 ' A' ' 18' ' ' THR . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.434 ' O ' HG23 ' A' ' 17' ' ' THR . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.749 HG23 ' CE1' ' A' ' 16' ' ' TYR . 27.9 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.799 0.333 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.649 HG23 ' HD2' ' A' ' 16' ' ' TYR . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.419 ' O ' ' N ' ' A' ' 15' ' ' PHE . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.649 ' HD2' HG23 ' A' ' 7' ' ' ILE . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.551 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p . . . . . 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.623 ' O ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 8' ' ' HIS . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.526 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB1' HD12 ' A' ' 9' ' ' ILE . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.605 ' HE1' HG23 ' A' ' 18' ' ' THR . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.605 HG23 ' HE1' ' A' ' 16' ' ' TYR . 0.6 OUTLIER . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.421 ' HB3' ' OG1' ' A' ' 17' ' ' THR . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 121.082 0.468 . . . . 0.0 110.766 . . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.527 ' O ' HD13 ' A' ' 9' ' ' ILE . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.527 HD13 ' O ' ' A' ' 8' ' ' HIS . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.455 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.71 ' CD1' HG23 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.421 ' OG1' ' HB3' ' A' ' 6' ' ' ARG . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.617 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 . . . . . 0 N--CA 1.455 -0.206 0 CA-C-O 120.972 0.415 . . . . 0.0 111.101 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.847 HD11 HG22 ' A' ' 18' ' ' THR . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.449 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.508 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.508 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.523 ' CE1' HG23 ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.847 HG22 HD11 ' A' ' 7' ' ' ILE . 82.7 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.944 0.402 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.93 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . 6.8 m170 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.807 HD11 ' HB3' ' A' ' 16' ' ' TYR . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.441 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.93 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.449 ' O ' HG23 ' A' ' 17' ' ' THR . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.702 ' CG2' HD11 ' A' ' 7' ' ' ILE . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 121.001 0.429 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.638 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . 0.717 ' O ' HD13 ' A' ' 9' ' ' ILE . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.717 HD13 ' O ' ' A' ' 8' ' ' HIS . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.638 ' CD1' HG23 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 26.6 p . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.682 ' HB2' HG22 ' A' ' 17' ' ' THR . 2.6 mtm-85 . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.961 0.41 . . . . 0.0 111.399 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 16' ' ' TYR . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.432 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.454 ' HD2' HG23 ' A' ' 7' ' ' ILE . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.682 HG22 ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.411 HG21 ' OH ' ' A' ' 16' ' ' TYR . 46.3 p . . . . . 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 44.6 mmt-85 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.186 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.852 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.1 OUTLIER -72.03 142.52 49.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.817 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -148.41 132.06 16.86 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.114 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.725 HD11 ' HD2' ' A' ' 5' ' ' LYS . 3.4 mp -140.6 111.69 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.033 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.416 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 3.9 m80 -146.8 126.59 13.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.655 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.8 mm -127.4 115.18 39.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.233 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.06 -147.0 7.11 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.221 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -74.27 65.54 5.36 Favored 'Trans proline' 0 N--CA 1.463 -0.31 0 C-N-CA 122.39 2.06 . . . . 0.0 111.76 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.51 21.47 37.41 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.856 -0.688 . . . . 0.0 111.908 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.41 84.37 2.0 Allowed 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.773 0.32 . . . . 0.0 110.674 -179.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.56 130.4 36.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.155 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -142.45 36.76 1.5 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.838 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.449 ' HD2' HG23 ' A' ' 7' ' ' ILE . 42.3 t80 -89.93 113.56 25.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.779 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 17' ' ' THR . 6.7 t -147.34 107.02 3.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.063 -179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.852 HG22 ' HE3' ' A' ' 5' ' ' LYS . 46.0 p -107.67 -68.22 0.91 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.872 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.6 mmtm . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.293 -0.861 . . . . 0.0 111.005 -179.999 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.5 mmt85 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.723 0.297 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.824 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -68.14 135.69 52.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.041 -179.915 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.92 117.59 5.4 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.653 179.807 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.924 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -112.11 111.74 37.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.18 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 p-80 -150.39 113.94 4.95 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.822 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.66 141.8 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.057 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -134.54 -146.38 5.4 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.403 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -64.06 69.64 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.739 2.293 . . . . 0.0 112.058 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.407 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 73.08 26.33 71.15 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.094 -179.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -103.46 73.8 1.22 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.968 0.413 . . . . 0.0 110.553 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -56.69 96.24 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.297 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -126.89 31.4 5.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.764 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.924 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.4 t80 -95.63 120.03 35.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.551 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.1 t -139.54 130.39 26.14 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.092 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.824 HG22 ' HE3' ' A' ' 5' ' ' LYS . 63.0 p -110.65 -74.51 0.64 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.6 tmmm? . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.92 -179.941 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 12.0 mtt180 . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.789 0.328 . . . . 0.0 111.244 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.859 ' HE2' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -55.48 139.8 42.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.184 -179.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.425 ' HB2' ' CE1' ' A' ' 8' ' ' HIS . 3.3 ptt85 -146.44 109.12 4.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.073 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.414 HG13 ' NZ ' ' A' ' 5' ' ' LYS . 7.5 mt -100.52 114.79 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.906 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 18.4 m170 -135.6 125.39 25.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.804 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.47 137.64 36.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.246 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -138.46 -148.65 5.35 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.266 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.5 63.1 3.68 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.398 2.065 . . . . 0.0 111.86 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.7 25.37 27.79 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.854 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.78 81.26 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.848 0.356 . . . . 0.0 110.72 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.84 105.42 1.0 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.067 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.402 ' CB ' ' HB2' ' A' ' 8' ' ' HIS . 45.1 m-85 -129.39 33.12 4.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.875 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.442 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 37.3 t80 -90.09 117.86 29.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.466 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -135.05 124.31 24.58 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.264 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.859 HG22 ' HE2' ' A' ' 5' ' ' LYS . 21.5 p -103.49 -60.33 1.58 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.908 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.9 tttt . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.288 -0.863 . . . . 0.0 110.865 179.975 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.885 0.374 . . . . 0.0 111.211 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.737 ' CE ' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -63.26 159.74 17.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.757 179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -140.82 91.18 2.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.285 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.691 HG22 HD11 ' A' ' 9' ' ' ILE . 18.6 mt -99.85 112.27 31.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.626 179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -128.14 128.13 44.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.847 0.356 . . . . 0.0 111.219 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.691 HD11 HG22 ' A' ' 7' ' ' ILE . 3.8 mp -132.71 104.05 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.976 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -87.52 -146.69 11.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.712 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.29 69.82 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.911 2.408 . . . . 0.0 111.795 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.99 22.5 68.56 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.581 -0.818 . . . . 0.0 111.699 -179.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -114.43 75.23 0.92 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.906 0.384 . . . . 0.0 110.465 -179.98 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -58.95 97.26 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.35 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.429 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 19.1 m-85 -106.11 66.22 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.547 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.464 ' CZ ' ' HE2' ' A' ' 5' ' ' LYS . 5.8 t80 -89.91 119.14 30.02 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.693 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 t -149.38 138.1 21.05 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.71 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.737 HG22 ' CE ' ' A' ' 5' ' ' LYS . 17.2 p -107.67 -63.89 1.26 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.958 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' N ' ' OG1' ' A' ' 18' ' ' THR . 13.8 tptm . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.252 -0.88 . . . . 0.0 110.845 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.852 0.358 . . . . 0.0 111.184 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.9 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -56.34 165.31 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.019 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.98 120.09 10.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.969 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.562 HD11 ' HE2' ' A' ' 5' ' ' LYS . 3.8 mt -127.36 111.88 26.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.054 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.401 ' HB2' ' HB2' ' A' ' 15' ' ' PHE . 66.3 m-70 -150.06 113.99 5.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.871 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.758 HD11 ' HB2' ' A' ' 16' ' ' TYR . 3.2 mp -138.64 103.94 2.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.1 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -129.1 -137.05 4.23 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.186 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HD2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_exo -50.26 86.04 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.836 2.358 . . . . 0.0 111.657 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.66 27.06 8.43 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.274 -0.965 . . . . 0.0 110.89 -178.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HD2' ' A' ' 11' ' ' PRO . 9.1 mtp180 -103.23 64.72 0.84 Allowed 'General case' 0 N--CA 1.453 -0.322 0 CA-C-O 120.912 0.387 . . . . 0.0 111.374 -178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.55 92.64 0.46 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.045 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.401 ' HB2' ' HB2' ' A' ' 8' ' ' HIS . 80.6 m-85 -122.33 37.67 4.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.02 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.758 ' HB2' HD11 ' A' ' 9' ' ' ILE . 25.3 t80 -90.03 96.15 10.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.699 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.7 p -128.67 138.51 52.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.941 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.9 HG22 ' HE3' ' A' ' 5' ' ' LYS . 30.2 p -106.39 -64.25 1.19 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.893 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.0 mmtt . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.19 -0.909 . . . . 0.0 111.137 179.926 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 6.3 mmm180 . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 120.813 0.34 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.726 ' CG ' HD11 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -174.71 -165.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.921 179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 10.7 mtt-85 -139.69 96.64 3.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.895 0.379 . . . . 0.0 111.0 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.726 HD11 ' CG ' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -112.03 112.08 38.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.779 179.933 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 13.2 m170 -127.19 128.26 45.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.873 0.368 . . . . 0.0 111.186 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.626 ' N ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -119.16 129.84 74.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.894 179.719 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -140.73 -150.64 5.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.76 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.58 73.64 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.901 2.401 . . . . 0.0 111.87 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.91 25.35 75.68 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.117 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.412 ' H ' ' HG2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -113.99 74.53 0.88 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.853 0.359 . . . . 0.0 110.488 179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.89 99.72 0.36 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.3 -179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -108.01 52.96 0.7 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.605 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.689 ' CG ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.87 109.24 20.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.711 -179.908 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 t -134.89 106.19 6.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.98 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.707 HG22 ' CE ' ' A' ' 5' ' ' LYS . 10.2 p -89.84 165.8 13.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.967 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 32.3 mttt . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.201 -0.904 . . . . 0.0 110.938 179.967 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 50.2 mtm-85 . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 120.776 0.322 . . . . 0.0 111.158 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.538 ' CE ' HG22 ' A' ' 18' ' ' THR . 0.1 OUTLIER -140.94 -171.16 3.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.006 179.949 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 25.0 mmm180 -134.48 98.62 4.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.584 179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.505 HG22 ' CD1' ' A' ' 9' ' ' ILE . 3.1 mt -99.88 116.43 43.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.145 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.0 m-70 -137.12 122.84 19.88 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 7' ' ' ILE . 3.9 mp -143.02 105.61 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.151 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -119.65 -139.43 5.93 Favored Glycine 0 CA--C 1.519 0.333 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.464 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.51 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 74.6 Cg_exo -50.64 86.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.77 2.314 . . . . 0.0 111.835 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 49.65 26.4 7.69 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.211 -178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.51 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 1.5 mtt-85 -99.27 64.29 1.35 Allowed 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.858 0.361 . . . . 0.0 111.232 -179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.75 87.35 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.048 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 25.2 m-85 -121.47 53.98 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.758 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.489 ' CD1' HG23 ' A' ' 7' ' ' ILE . 5.5 t80 -90.01 102.41 15.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.611 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.6 t -114.96 123.89 50.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.841 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.538 HG22 ' CE ' ' A' ' 5' ' ' LYS . 36.3 p -89.9 -174.15 4.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.955 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 pttt . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.207 -0.902 . . . . 0.0 110.87 179.946 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.488 1.437 0 CA-C-O 120.731 0.301 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.642 ' HD3' HD11 ' A' ' 7' ' ' ILE . 2.1 ttmt -113.61 167.54 10.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.525 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.467 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 20.6 mtt180 -168.07 114.87 0.7 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.734 179.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.642 HD11 ' HD3' ' A' ' 5' ' ' LYS . 3.5 mt -121.13 124.23 71.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.215 -179.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -150.1 115.48 5.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.886 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.34 130.11 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.151 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.9 -156.46 9.6 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.432 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.8 Cg_endo -74.19 63.36 5.22 Favored 'Trans proline' 0 N--CA 1.463 -0.277 0 C-N-CA 122.449 2.1 . . . . 0.0 111.838 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.72 20.33 37.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.867 -0.683 . . . . 0.0 111.828 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.61 86.64 2.53 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.798 0.332 . . . . 0.0 110.765 -179.757 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -72.15 123.55 23.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.263 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -130.88 49.78 2.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.733 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.616 ' CE1' HG23 ' A' ' 18' ' ' THR . 49.3 t80 -89.97 91.88 8.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.797 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -119.67 92.91 3.9 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.087 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.616 HG23 ' CE1' ' A' ' 16' ' ' TYR . 47.9 p -89.92 -173.38 3.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.815 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.238 -0.887 . . . . 0.0 110.985 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.753 0.311 . . . . 0.0 111.231 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.576 ' HE3' ' HB ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -172.79 -178.57 1.9 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.086 -179.927 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 33.7 ptt180 -145.6 119.82 9.53 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.475 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.617 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.4 mt -120.22 111.89 34.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.316 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 4.5 t60 -150.03 125.01 9.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.148 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.16 133.47 68.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.525 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -123.58 -155.46 9.25 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.201 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.513 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 41.6 Cg_endo -73.98 75.12 3.29 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.281 1.987 . . . . 0.0 112.18 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.7 22.42 64.26 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.172 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.513 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -109.28 79.07 1.18 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.946 0.403 . . . . 0.0 110.752 -179.799 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -53.92 114.53 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.306 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -146.09 37.74 1.06 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.73 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.617 ' CD1' HG23 ' A' ' 7' ' ' ILE . 7.0 t80 -97.89 114.36 26.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.762 -179.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.416 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 9.3 p -131.1 137.21 48.98 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.576 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 22.0 p -126.35 64.34 1.25 Allowed 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.729 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 17.5 mmtt . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.014 -179.857 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 9.2 ttp180 . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 120.846 0.355 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.576 ' HD3' HD11 ' A' ' 7' ' ' ILE . 18.1 ttmt -96.58 164.92 12.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.474 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -160.32 118.13 2.56 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.931 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.576 HD11 ' HD3' ' A' ' 5' ' ' LYS . 19.5 mt -125.21 126.32 70.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.057 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -149.97 120.44 7.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.91 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mp -111.58 131.79 61.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.214 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -126.52 -148.39 7.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.358 179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.429 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.9 Cg_endo -78.19 69.47 7.54 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.492 2.128 . . . . 0.0 111.9 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.8 24.77 31.68 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.626 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.429 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -124.69 79.98 1.82 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.762 0.315 . . . . 0.0 110.739 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -77.79 105.95 9.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.091 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -111.29 55.38 0.66 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.462 ' CZ ' ' CG2' ' A' ' 18' ' ' THR . 76.2 t80 -90.02 92.04 8.82 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.593 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 p -118.55 103.23 9.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.195 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.492 HG22 ' HE2' ' A' ' 5' ' ' LYS . 17.7 p -94.83 -59.88 1.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.882 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.0 pttt . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.381 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.8 ptt180 . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 120.932 0.396 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.874 ' HE3' HG22 ' A' ' 18' ' ' THR . 18.6 tttt -99.0 153.67 18.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.74 128.61 8.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.843 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.581 ' N ' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -138.54 127.97 32.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.908 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.434 ' CE1' ' HB3' ' A' ' 15' ' ' PHE . 2.6 p80 -149.89 114.0 5.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.835 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mp -112.11 141.93 26.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.17 -179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.68 -151.27 8.04 Favored Glycine 0 CA--C 1.518 0.241 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.31 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.416 ' C ' ' HD3' ' A' ' 13' ' ' ARG . 66.3 Cg_endo -74.51 65.29 5.6 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.473 2.115 . . . . 0.0 111.97 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 25.42 29.29 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.706 -0.759 . . . . 0.0 111.849 -179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.416 ' HD3' ' C ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -113.98 82.3 1.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.864 0.364 . . . . 0.0 110.59 -179.933 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.84 134.86 57.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.15 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.434 ' HB3' ' CE1' ' A' ' 8' ' ' HIS . 23.7 m-85 -162.54 50.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.731 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.503 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -90.05 114.7 26.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.946 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 44.8 p -126.99 138.08 53.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.781 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.874 HG22 ' HE3' ' A' ' 5' ' ' LYS . 6.3 p -133.38 -170.0 2.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.997 -179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.4 tptp . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.816 179.97 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 13.6 tpp180 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.887 0.375 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.703 ' HE2' HG22 ' A' ' 18' ' ' THR . 2.4 ttmt -105.4 163.08 12.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.509 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.448 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 26.1 ptt-85 -154.7 120.39 5.14 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.693 179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.2 mp -118.11 121.34 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.123 -179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.8 m80 -134.2 128.05 33.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.835 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.6 mp -130.59 106.94 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.184 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -98.57 -149.53 24.9 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.341 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 58.0 Cg_endo -73.94 66.86 5.0 Favored 'Trans proline' 0 N--CA 1.462 -0.325 0 C-N-CA 122.397 2.065 . . . . 0.0 112.311 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.02 24.89 33.37 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.949 -0.643 . . . . 0.0 111.825 -179.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -107.78 80.68 1.41 Allowed 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.815 0.34 . . . . 0.0 110.78 -179.612 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.01 87.04 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.032 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -113.37 62.32 0.64 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.915 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.816 ' CD1' HG23 ' A' ' 7' ' ' ILE . 8.7 t80 -102.24 110.98 23.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.839 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -130.79 112.71 13.29 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.073 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.703 HG22 ' HE2' ' A' ' 5' ' ' LYS . 19.5 p -90.08 -169.66 2.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.758 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 4.8 tptm . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.918 179.922 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 21.4 mtm-85 . . . . . 0 N--CA 1.487 1.425 0 CA-C-O 120.808 0.337 . . . . 0.0 111.232 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.747 ' HD3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -81.33 176.69 9.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.875 -179.998 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -161.79 123.31 2.79 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.888 179.633 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.567 HG23 ' HA ' ' A' ' 16' ' ' TYR . 1.4 mp -128.54 112.08 25.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.12 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 3.9 p80 -150.11 128.12 11.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.2 mp -104.89 130.17 56.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.066 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -122.89 -152.31 8.52 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.554 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' ' HD2' ' A' ' 13' ' ' ARG . 17.7 Cg_exo -66.82 63.82 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.946 2.431 . . . . 0.0 111.843 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.17 23.11 57.82 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.661 -0.781 . . . . 0.0 111.775 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.403 ' HD2' ' O ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.46 72.06 0.86 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.024 0.44 . . . . 0.0 110.551 -179.84 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -63.01 123.78 19.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.282 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -127.6 53.22 1.77 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.689 179.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.567 ' HA ' HG23 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -89.85 101.72 14.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.845 -179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 t -139.52 106.58 5.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.878 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.747 HG22 ' HD3' ' A' ' 5' ' ' LYS . 30.6 p -93.69 21.67 6.2 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.329 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 120.803 0.335 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.587 ' CE ' HD11 ' A' ' 7' ' ' ILE . 3.6 tttt -115.0 154.22 29.2 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.386 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 13.0 mtt-85 -156.82 122.46 4.76 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.905 179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.587 HD11 ' CE ' ' A' ' 5' ' ' LYS . 0.4 OUTLIER -132.49 111.99 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.096 -179.907 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -139.26 125.75 20.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.365 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 9' ' ' ILE . 4.0 mp -112.06 125.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.341 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.99 -147.53 19.85 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.286 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.482 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 57.7 Cg_endo -74.67 63.7 5.7 Favored 'Trans proline' 0 N--CA 1.461 -0.439 0 C-N-CA 122.378 2.052 . . . . 0.0 111.431 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.95 15.34 49.21 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.582 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.482 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-O 120.759 0.314 . . . . 0.0 110.667 -179.7 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -84.01 114.11 21.49 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.219 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -98.48 70.2 1.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.759 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -90.08 109.29 20.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -142.39 94.81 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.509 HG22 ' CE ' ' A' ' 5' ' ' LYS . 6.6 p -100.47 -171.82 2.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.881 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.4 ttmt . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.882 179.884 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.427 0 CA-C-O 120.871 0.367 . . . . 0.0 111.248 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.796 ' HD2' HD11 ' A' ' 7' ' ' ILE . 1.1 ptpt -83.8 -171.25 3.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.176 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.411 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 42.0 mtt-85 -151.1 103.01 3.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.33 179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.796 HD11 ' HD2' ' A' ' 5' ' ' LYS . 1.1 mp -101.99 111.9 33.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.97 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -149.4 128.06 12.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.626 -179.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.8 mp -128.2 142.1 44.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.161 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -133.9 -139.14 4.1 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.556 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -65.16 69.52 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.825 2.35 . . . . 0.0 112.157 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.01 24.6 68.75 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.976 -179.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.409 ' HB3' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -105.6 76.33 1.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.98 0.419 . . . . 0.0 110.49 179.91 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.63 68.01 0.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.32 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE2' ' HB3' ' A' ' 13' ' ' ARG . 37.5 m-85 -93.89 52.18 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.71 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.699 ' CD1' HG23 ' A' ' 7' ' ' ILE . 1.7 t80 -89.98 110.49 21.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.662 -179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 t -117.57 138.8 51.68 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.626 HG22 ' CE1' ' A' ' 16' ' ' TYR . 19.8 p -117.26 -40.27 3.11 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 mtmt . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.245 -0.883 . . . . 0.0 110.861 179.957 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.837 0.351 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.565 ' HB2' ' HA ' ' A' ' 18' ' ' THR . 0.1 OUTLIER -159.37 172.67 17.53 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.894 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.44 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -162.63 119.53 1.97 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.783 179.293 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 9' ' ' ILE . 2.9 mt -115.39 130.55 69.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.279 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.597 ' C ' HD12 ' A' ' 9' ' ' ILE . 7.6 m-70 -146.09 128.16 15.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.866 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.638 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -132.75 103.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.124 179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -107.82 -143.93 11.02 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.183 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.95 64.12 4.07 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.305 2.003 . . . . 0.0 111.857 179.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.02 22.62 32.27 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.827 -179.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.21 82.91 1.67 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.8 0.334 . . . . 0.0 110.654 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -75.14 111.74 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.311 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -129.96 54.59 1.84 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.556 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.543 ' CZ ' HG21 ' A' ' 18' ' ' THR . 66.4 t80 -89.91 94.52 9.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.038 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.48 68.27 0.73 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.954 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.565 ' HA ' ' HB2' ' A' ' 5' ' ' LYS . 15.0 p -96.04 137.38 35.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.916 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.231 -0.89 . . . . 0.0 110.972 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 23.3 mmm180 . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.848 0.356 . . . . 0.0 111.248 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.72 ' HE3' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -88.04 146.27 25.55 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.554 -179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.441 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.1 mtm-85 -123.23 84.95 2.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.051 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.655 HG23 ' HD1' ' A' ' 16' ' ' TYR . 5.4 mt -92.67 112.33 25.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.895 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 15' ' ' PHE . 6.3 m170 -133.81 128.32 34.49 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.7 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.7 mt -150.22 108.5 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.392 -179.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -102.5 -137.8 9.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.332 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.419 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.1 Cg_endo -74.43 69.32 5.09 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.409 2.073 . . . . 0.0 112.074 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 85.41 26.51 35.84 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.887 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.419 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -109.49 79.48 1.22 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.851 0.358 . . . . 0.0 110.702 -179.896 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -61.96 83.94 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.998 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.436 ' HB2' ' O ' ' A' ' 8' ' ' HIS . 12.5 m-85 -106.87 43.11 1.19 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.078 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.655 ' HD1' HG23 ' A' ' 7' ' ' ILE . 43.9 t80 -89.96 95.53 10.26 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.551 179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.1 p -127.74 125.64 40.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.72 HG22 ' HE3' ' A' ' 5' ' ' LYS . 4.7 p -89.98 -166.25 1.54 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.713 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.302 -0.856 . . . . 0.0 110.848 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.861 0.362 . . . . 0.0 111.105 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.588 ' HE2' HD11 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -120.79 -170.27 1.97 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.915 179.924 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 12.7 ttt85 -147.97 107.51 3.95 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.786 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.588 HD11 ' HE2' ' A' ' 5' ' ' LYS . 5.1 mt -116.97 113.8 43.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.119 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.5 p80 -149.97 128.11 12.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.971 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.629 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.4 mp -120.23 142.22 36.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.185 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.465 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -131.48 -127.38 2.85 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.37 -179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 72.6 Cg_endo -96.85 93.34 0.08 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 123.031 2.487 . . . . 0.0 112.972 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 58.16 56.67 23.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.848 179.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.495 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -162.16 51.36 0.21 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.953 0.406 . . . . 0.0 110.663 179.601 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -43.15 127.45 4.33 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.842 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 23.2 m-85 -137.9 60.08 1.64 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.619 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.425 ' CE1' ' CG2' ' A' ' 18' ' ' THR . 29.0 t80 -89.78 98.07 11.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 19.2 p -111.58 132.1 54.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.69 179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.588 ' HB ' ' HE3' ' A' ' 5' ' ' LYS . 16.9 p -117.99 -165.18 1.07 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.981 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.387 0 CA-C-O 120.916 0.389 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.772 ' HE2' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -51.49 156.73 1.2 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.12 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.87 ' HG2' HG23 ' A' ' 17' ' ' THR . 0.0 OUTLIER -136.75 115.37 12.0 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 121.007 0.432 . . . . 0.0 111.41 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.772 HD11 ' HE2' ' A' ' 5' ' ' LYS . 21.3 mt -125.87 111.68 27.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.773 179.542 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.438 ' CE1' ' HB2' ' A' ' 6' ' ' ARG . 0.0 OUTLIER -150.36 128.22 11.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.889 0.376 . . . . 0.0 111.042 179.677 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.6 mm -107.62 123.22 62.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -103.31 -154.05 24.15 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.427 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.488 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 60.8 Cg_endo -77.21 69.44 7.11 Favored 'Trans proline' 0 N--CA 1.461 -0.394 0 C-N-CA 122.525 2.15 . . . . 0.0 111.707 179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 86.67 23.47 42.55 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.368 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.488 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -135.29 79.29 1.78 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.818 0.342 . . . . 0.0 110.864 -179.555 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.46 96.71 1.19 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.872 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -86.97 52.97 2.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.058 0.456 . . . . 0.0 111.033 -179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.54 ' HD1' HG23 ' A' ' 7' ' ' ILE . 13.8 t80 -89.88 124.94 35.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.214 179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.87 HG23 ' HG2' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -149.35 125.65 10.82 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-O 121.187 0.518 . . . . 0.0 111.208 -179.792 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.598 HG22 ' HD3' ' A' ' 5' ' ' LYS . 1.4 p -115.12 132.59 56.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.824 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.965 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 . . . . . 0 N--CA 1.486 1.358 0 CA-C-O 120.814 0.34 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.656 ' HD2' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -82.05 -164.61 0.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.002 179.919 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.424 ' N ' ' HG3' ' A' ' 5' ' ' LYS . 14.4 mtt180 -140.57 99.06 3.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.74 179.422 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.656 HD11 ' HD2' ' A' ' 5' ' ' LYS . 1.6 mt -102.73 111.3 32.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.698 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.471 ' CD2' ' O ' ' A' ' 7' ' ' ILE . 14.1 m80 -145.66 128.13 15.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.151 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.1 mm -116.25 123.55 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.773 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.3 -160.27 29.2 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.866 -179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_exo -66.9 66.79 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.022 2.481 . . . . 0.0 111.977 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.45 75.35 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.586 -0.816 . . . . 0.0 111.885 -179.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.88 74.79 0.88 Allowed 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.972 0.415 . . . . 0.0 110.311 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.78 118.88 11.62 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.458 -179.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.465 ' CZ ' ' HB2' ' A' ' 8' ' ' HIS . 1.8 p90 -145.04 47.94 1.31 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.561 179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.58 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -89.85 129.29 36.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.621 -179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.85 146.32 50.96 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.274 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.628 HG22 ' HD3' ' A' ' 5' ' ' LYS . 18.4 p -112.01 32.47 5.47 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.912 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.4 pttp . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.23 -0.891 . . . . 0.0 110.907 179.988 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 56.2 mtm180 . . . . . 0 N--CA 1.486 1.363 0 CA-C-O 120.966 0.412 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.518 ' HE2' ' OG1' ' A' ' 18' ' ' THR . 0.5 OUTLIER -177.89 155.29 0.98 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.946 -179.932 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.34 141.44 19.39 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.644 179.621 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.465 ' CG1' ' HB ' ' A' ' 18' ' ' THR . 1.2 mp -128.67 111.94 24.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.121 -179.608 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 7.7 m170 -125.54 128.05 47.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.922 -179.961 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 7' ' ' ILE . 4.0 mp -128.23 109.59 19.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.034 -179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -117.92 -145.58 7.95 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.5 179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.86 65.0 2.46 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.447 2.098 . . . . 0.0 111.946 179.73 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.15 23.33 41.31 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.061 -179.351 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.402 ' CD ' ' N ' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -101.38 79.11 1.94 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 -179.872 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.67 80.15 0.07 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.305 -179.691 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.9 m-85 -106.36 50.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.537 179.67 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.853 ' CZ ' HG22 ' A' ' 18' ' ' THR . 20.2 t80 -90.25 119.82 30.88 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.756 -179.813 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 62.5 p -150.03 60.95 0.98 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.227 -179.932 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.853 HG22 ' CZ ' ' A' ' 16' ' ' TYR . 10.7 t -101.5 48.99 0.88 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.514 179.761 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.5 tptt . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.167 -0.921 . . . . 0.0 110.817 -179.995 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.004 0.431 . . . . 0.0 111.058 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 17' ' ' THR . 0.0 OUTLIER -53.4 -171.93 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.586 -179.739 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.416 ' O ' ' HE2' ' A' ' 5' ' ' LYS . 51.1 ttt-85 -107.21 118.73 37.49 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.913 0.387 . . . . 0.0 111.865 -179.046 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.557 HG23 ' CD2' ' A' ' 16' ' ' TYR . 0.7 OUTLIER -125.72 111.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.599 179.448 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.0 m-70 -138.9 128.17 24.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.883 0.373 . . . . 0.0 111.308 -179.748 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.525 ' N ' HD12 ' A' ' 9' ' ' ILE . 3.7 mp -128.57 104.05 10.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.056 179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 12' ' ' GLY . . . -104.19 -150.21 20.76 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.582 179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -65.92 65.87 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.875 2.383 . . . . 0.0 111.818 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 10' ' ' GLY . . . 80.57 20.89 65.26 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.817 -179.222 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.413 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -111.12 77.83 1.07 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.885 0.374 . . . . 0.0 110.506 -179.88 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.54 110.22 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.328 -179.776 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 9.3 m-85 -114.84 44.23 1.81 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.599 179.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.749 ' CE1' HG23 ' A' ' 18' ' ' THR . 18.5 t80 -89.89 122.13 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.625 -179.915 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.485 ' O ' ' HB2' ' A' ' 5' ' ' LYS . 4.9 t -150.34 108.86 3.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.847 -179.662 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.749 HG23 ' CE1' ' A' ' 16' ' ' TYR . 27.9 p -96.66 44.66 1.06 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.035 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.171 -0.919 . . . . 0.0 111.48 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 18.7 mtm180 . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 120.857 0.36 . . . . 0.0 111.21 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.535 ' HD2' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -46.73 142.91 3.03 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.475 179.798 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 -92.08 87.47 6.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.942 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.649 HG23 ' HD2' ' A' ' 16' ' ' TYR . 0.6 OUTLIER -107.26 122.1 60.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.019 -179.749 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.419 ' O ' ' N ' ' A' ' 15' ' ' PHE . 17.9 m-70 -149.73 128.24 12.28 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.743 -179.911 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 14.4 mm -124.12 142.08 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.896 0.379 . . . . 0.0 111.107 -179.951 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -139.51 -158.61 7.69 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.635 -179.828 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -66.66 64.59 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.901 2.401 . . . . 0.0 112.003 -179.892 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.82 -0.99 89.33 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.595 -0.812 . . . . 0.0 111.967 -179.172 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.441 ' HB2' ' CZ ' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -107.76 58.07 0.62 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.115 0.483 . . . . 0.0 110.443 179.738 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -62.44 118.94 8.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.728 -179.475 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.441 ' CZ ' ' HB2' ' A' ' 13' ' ' ARG . 3.3 m-85 -106.01 60.81 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.377 179.36 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.649 ' HD2' HG23 ' A' ' 7' ' ' ILE . 2.9 t80 -89.83 122.2 32.67 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.672 -179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 p -138.43 121.51 16.79 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.493 -179.916 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.551 HG23 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 p -96.21 -91.18 0.23 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.278 -179.515 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.0 ttpt . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.242 -0.885 . . . . 0.0 110.896 -179.914 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 CA-C-O 120.856 0.36 . . . . 0.0 111.096 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.682 ' HG3' HG22 ' A' ' 18' ' ' THR . 0.0 OUTLIER -61.98 -155.98 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.672 -179.944 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -93.15 50.54 1.54 Allowed 'General case' 0 N--CA 1.456 -0.172 0 CA-C-O 120.972 0.415 . . . . 0.0 110.31 179.667 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 16' ' ' TYR . 5.5 mt -89.92 111.59 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.92 -179.708 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.623 ' O ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -150.28 128.16 11.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.742 -179.896 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 8' ' ' HIS . 18.2 mm -125.68 141.89 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.932 0.396 . . . . 0.0 111.258 -179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -115.85 -157.17 11.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.526 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 55.6 Cg_endo -76.0 70.39 5.98 Favored 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.431 2.087 . . . . 0.0 111.605 179.672 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.08 12.15 63.96 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.545 -178.924 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.526 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -125.43 87.65 2.74 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-O 120.816 0.341 . . . . 0.0 110.568 -179.715 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.482 ' HB1' HD12 ' A' ' 9' ' ' ILE . . . -87.84 125.56 34.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.401 -179.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -133.11 59.02 1.75 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.472 179.632 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.605 ' HE1' HG23 ' A' ' 18' ' ' THR . 0.2 OUTLIER -90.01 146.54 24.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.431 -179.918 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.26 140.92 22.61 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-O 121.019 0.437 . . . . 0.0 111.233 -179.786 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.682 HG22 ' HG3' ' A' ' 5' ' ' LYS . 0.6 OUTLIER -130.5 -174.36 3.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.845 179.681 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.268 -0.872 . . . . 0.0 110.89 179.956 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 120.962 0.41 . . . . 0.0 111.084 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.455 ' CG ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -53.13 -175.03 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.813 -179.82 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.421 ' HB3' ' OG1' ' A' ' 17' ' ' THR . 0.1 OUTLIER -107.27 60.58 0.62 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.766 179.992 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' CD1' ' A' ' 16' ' ' TYR . 1.1 mp -89.87 118.43 35.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.132 -179.825 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.527 ' O ' HD13 ' A' ' 9' ' ' ILE . 57.5 m-70 -131.28 127.97 38.85 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.527 HD13 ' O ' ' A' ' 8' ' ' HIS . 24.2 mm -132.91 137.37 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.076 179.942 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -143.24 -151.46 5.48 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.441 -179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.455 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.4 Cg_endo -78.27 71.69 6.62 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.578 2.185 . . . . 0.0 112.149 179.88 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.15 19.07 54.38 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.731 -0.747 . . . . 0.0 111.879 -179.225 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.455 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -118.6 81.23 1.66 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.839 0.352 . . . . 0.0 110.611 -179.827 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -76.9 112.05 13.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.203 -179.947 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -129.67 54.66 1.82 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.71 ' CD1' HG23 ' A' ' 7' ' ' ILE . 2.1 t80 -89.94 99.4 12.41 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.971 -179.84 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.421 ' OG1' ' HB3' ' A' ' 6' ' ' ARG . 1.4 p -109.2 113.17 25.79 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.779 179.845 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.617 HG21 ' CZ ' ' A' ' 16' ' ' TYR . 1.4 t -139.8 103.03 4.56 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.87 -179.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.798 -179.972 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 61.1 ttp180 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.813 0.34 . . . . 0.0 111.188 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HE2' ' HA ' ' A' ' 18' ' ' THR . 0.2 OUTLIER -135.21 -175.59 3.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.965 -179.887 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 4.9 mtm180 -161.97 125.11 3.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.101 179.572 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.847 HD11 HG22 ' A' ' 18' ' ' THR . 15.2 mt -134.22 117.95 26.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.956 -179.959 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 70.4 m-70 -143.22 128.26 18.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.053 -179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 25.6 mm -121.2 136.01 59.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.113 179.855 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.449 ' C ' ' HD2' ' A' ' 13' ' ' ARG . . . -140.4 -130.47 2.65 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.447 -179.875 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.508 ' HD2' ' CD ' ' A' ' 13' ' ' ARG . 71.7 Cg_endo -96.44 92.27 0.09 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 123.078 2.519 . . . . 0.0 112.952 -179.671 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 57.43 59.1 11.47 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.838 179.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.508 ' CD ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -163.13 54.05 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.051 0.453 . . . . 0.0 110.626 179.672 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -44.82 133.51 6.12 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.796 -179.786 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.418 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 25.8 m-85 -142.05 48.21 1.6 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.774 179.876 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.523 ' CE1' HG23 ' A' ' 18' ' ' THR . 58.1 t80 -89.88 105.97 18.16 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.654 -179.997 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 p -134.04 90.69 2.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.923 -179.946 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.847 HG22 HD11 ' A' ' 7' ' ' ILE . 82.7 p -95.32 37.59 1.17 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 179.996 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.3 ttmm . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.225 -0.893 . . . . 0.0 110.976 -179.968 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 120.775 0.321 . . . . 0.0 111.294 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.625 ' CD ' HG22 ' A' ' 18' ' ' THR . 0.2 OUTLIER -84.58 -172.52 4.22 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.981 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.93 123.31 4.02 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.894 179.551 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.93 HG23 ' CD1' ' A' ' 16' ' ' TYR . 3.1 mt -128.5 111.81 24.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.196 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.497 ' O ' HD13 ' A' ' 9' ' ' ILE . 6.8 m170 -150.15 128.03 11.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.905 179.931 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.807 HD11 ' HB3' ' A' ' 16' ' ' TYR . 29.7 mm -129.58 137.15 57.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.248 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -124.89 -145.58 6.62 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.392 179.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.441 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 73.8 Cg_endo -77.15 71.94 6.1 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -179.942 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.64 20.18 51.93 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.973 -179.538 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -102.0 81.39 2.11 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.881 0.372 . . . . 0.0 110.458 -179.761 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -81.39 94.0 6.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.408 -179.66 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.416 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 28.7 p90 -140.67 34.87 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.922 0.391 . . . . 0.0 110.733 179.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.93 ' CD1' HG23 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -90.04 134.16 34.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.8 -179.953 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.449 HG23 ' O ' ' A' ' 17' ' ' THR . 8.4 t -150.26 113.22 4.81 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.134 179.855 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.702 ' CG2' HD11 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -101.65 82.61 2.3 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.828 179.636 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.6 mmtt . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.926 -179.988 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.601 0.239 . . . . 0.0 111.13 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.938 ' HD3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -126.82 165.68 18.87 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 120.771 0.319 . . . . 0.0 110.346 -179.878 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.444 ' N ' ' CG ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -161.92 123.21 2.72 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.744 179.256 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.938 HD11 ' HD3' ' A' ' 5' ' ' LYS . 1.0 OUTLIER -127.72 112.32 27.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.931 -179.75 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.717 ' O ' HD13 ' A' ' 9' ' ' ILE . 44.4 m170 -130.05 127.88 40.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.959 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.717 HD13 ' O ' ' A' ' 8' ' ' HIS . 11.2 mm -131.99 130.89 61.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.985 179.985 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.05 -140.16 2.88 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.497 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.431 ' HG2' ' HD3' ' A' ' 13' ' ' ARG . 90.7 Cg_endo -80.34 78.09 3.81 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.617 2.211 . . . . 0.0 112.1 -179.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.49 22.52 53.68 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.702 -0.761 . . . . 0.0 111.939 -179.4 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -116.02 76.76 1.04 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.856 0.36 . . . . 0.0 110.6 -179.888 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -87.58 80.42 8.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.172 -179.751 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 45.4 m-85 -106.88 66.23 0.68 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.862 179.785 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.638 ' CD1' HG23 ' A' ' 7' ' ' ILE . 3.6 t80 -104.45 93.87 5.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.721 179.959 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.7 p -134.83 112.45 10.72 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.491 HG22 ' HE2' ' A' ' 5' ' ' LYS . 26.6 p -89.95 -53.85 4.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.964 -179.892 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.866 -179.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.406 0 CA-C-O 120.944 0.402 . . . . 0.0 111.261 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.447 ' CE ' ' HA ' ' A' ' 18' ' ' THR . 0.0 OUTLIER -49.92 172.69 0.02 OUTLIER 'General case' 0 CA--C 1.518 -0.273 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.378 -179.959 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.682 ' HB2' HG22 ' A' ' 17' ' ' THR . 2.6 mtm-85 -126.65 109.33 11.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.399 -179.813 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 16' ' ' TYR . 25.0 mt -136.3 111.66 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.702 179.647 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 39.9 m-70 -150.16 128.15 11.86 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.942 -179.8 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.5 mm -101.49 134.15 42.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.963 179.853 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -121.26 -159.06 10.59 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.629 -179.76 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.45 62.79 0.78 Allowed 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.987 2.458 . . . . 0.0 111.851 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.45 17.51 64.11 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.65 -179.072 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.432 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 0.0 OUTLIER -121.42 72.06 0.99 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.871 0.367 . . . . 0.0 110.607 -179.89 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -57.23 112.56 1.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.327 -179.807 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.432 ' CE2' ' HB2' ' A' ' 13' ' ' ARG . 41.4 m-85 -106.32 62.76 0.65 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.647 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.454 ' HD2' HG23 ' A' ' 7' ' ' ILE . 8.9 t80 -100.6 131.32 46.57 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.971 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.682 HG22 ' HB2' ' A' ' 6' ' ' ARG . 7.3 t -150.01 118.32 6.42 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.782 179.562 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.447 ' HA ' ' CE ' ' A' ' 5' ' ' LYS . 46.3 p -133.25 -74.88 0.49 Allowed 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.938 -179.872 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.335 -0.841 . . . . 0.0 110.84 -179.954 . . . . . . . . 1 1 . 1 stop_ save_